Qrons

Advanced Stem-cell-based Solutions for Neuronal Injuries

Health Tech & Life Sciences
Active
Public Ari'el, Israel Founded 2016
Last updated 2026-06-18
Total raised
$500K
Stage
Public
Founded
2016
Headcount
4
HQ
Ari'el, Israel
Sector
Health Tech & Life Sciences

About

Qrons is a biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. Its approach seeks to marshal and leverage the remarkable advances made in the fields of artificial intelligence (AI), machine learning (ML), molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases.

The company has two product candidates for treating traumatic brain injuries, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material. QS100 is an injury-specific, 3D-printable, implantable MSC-synthetic hydrogel for treating penetrating brain injuries. QS200 is an injectable MSC-synthetic hydrogel for the treatment of concussions.

The company conducts its research in Israel under service agreements with Ariel University and has an ongoing sponsored research agreement with Dartmouth College.

Q&A

What is Qrons' primary focus?
Qrons is a biotechnology company focused on developing advanced stem-cell-based solutions for neuronal injuries and combating neuronal diseases.
What product candidates is Qrons developing for traumatic brain injuries?
Qrons has two product candidates: QS100, an injury-specific, 3D-printable, implantable MSC-synthetic hydrogel for penetrating brain injuries, and QS200, an injectable MSC-synthetic hydrogel for concussions.
Where does Qrons conduct its research?
Qrons conducts its research in Israel under service agreements with Ariel University and has an ongoing sponsored research agreement with Dartmouth College.
When was Qrons founded?
Qrons was founded in January 2016.
What is Qrons' current employee count?
Qrons has 4 employees, falling within the 1-10 employee bucket.
What is Qrons' current market capitalization?
Qrons' market capitalization is $199,800 USD.
What is Qrons' total funding raised to date?
Qrons has raised a total of $500,000 USD.
What is Qrons' current public status?
Qrons became public on OTC in August 2017.
Who are the co-founders of Qrons?
The co-founders of Qrons are Jonah Meer, who serves as CEO, CFO, and Director, and Ido Merfeld, who serves as President and Director.

Team · 2

Founder · Co-founder, CEO, CFO & Director
LinkedIn ↗
Founder · Co-founder, President & Director
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceMachine LearningBiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

1 Patents

Tags

medical-technologiesbiotechnologyalzheimers-diseasestem-cellsacademiaparkinsonregenerative-medicineneurology3d-technologyhospitalsartificial-intelligencemachine-learning
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteqrons.com/
LinkedInlinkedin.com/company/37398497

Identifiers & details

Former namesBioLabMart
Founded2016-1
Employees (exact)4
OfficesQueens
Market cap$200K
Status reasonPublic on OTC on Aug, 2017;

Radar intelligence

Patents

EPO2

Publications (Crossref)

Works1

Web history (Wayback)

Domainqrons.com